Basics BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. IPO Date: August 1, 1999 Sector: Healthcare Industry: Biotech Market Cap: $11.77B Activated in VL: True Average Daily Range Avg Daily Range: $0.87 | 1.65% Avg Daily Range (30 D): $1.23 | 2.03% Avg Daily Range (90 D): $0.93 | 1.46% Institutional Daily Volume Avg Daily Volume: 1.2M Avg Daily Volume (30 D): 1.53M Avg Daily Volume (90 D): 1.31M Trade Size Avg Trade Size (Sh.): 107 Avg Trade Size (Sh.) (30 D): 53 Avg Trade Size (Sh.) (90 D): 52 Institutional Trades Total Inst.Trades: 23,231 Avg Inst. Trade: $3.5M Avg Inst. Trade (30 D): $7.37M Avg Inst. Trade (90 D): $6.33M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 5 Market Closing Trades Avg Closing Trade: $10.59M Avg Closing Trade (30 D): $18.67M Avg Closing Trade (90 D): $20.06M Avg Closing Volume: 129.69K         News Apr 21, 2025 @ 12:00 PM Joshua Grass, John Kelly, and Lauren Daniel Join 5... Source: 5Am Ventures Apr 11, 2025 @ 7:06 AM 6 Stocks With Clear Price Dislocations That I Purc... Source: Sean Williams Apr 2, 2025 @ 7:06 PM BioMarin Seeks Label Expansion For Palynziq After ... Source: Vandana Singh Feb 20, 2025 @ 10:56 PM Why BioMarin Pharmaceutical Stock Zoomed Almost 5%... Source: Eric Volkman Feb 20, 2025 @ 2:39 PM Why Is BioMarin Stock Trading Higher On Thursday? Source: Vandana Singh Financials   TTM Q1 2025 Q4 2024 Basic EPS $2.75 $.97 $.66 Diluted EPS $2.7 $.95 $.65 Revenue $ 2.95B $ 745.15M $ 747.31M Gross Profit $ 2.34B $ 593.59M $ 611.17M Net Income / Loss $ 523.88M $ 185.69M $ 124.94M Operating Income / Loss $ 619.65M $ 223.89M $ 161.41M Cost of Revenue $ 606.61M $ 151.56M $ 136.14M Net Cash Flow $ 300.32M $ 107.38M $ 264.89M PE Ratio 0.00